- Home
- ALXO vs SCNX Comparison
ALXO vs SCNX Comparison
Compare ALXO & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- SCNX
- Stock Information
- Founded
- ALXO 2015
- SCNX 2010
- Country
- ALXO United States
- SCNX United States
- Employees
- ALXO N/A
- SCNX N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- SCNX Other Pharmaceuticals
- Sector
- ALXO Health Care
- SCNX Health Care
- Exchange
- ALXO Nasdaq
- SCNX Nasdaq
- Market Cap
- ALXO 24.0M
- SCNX 33.6M
- IPO Year
- ALXO 2020
- SCNX 2020
- Fundamental
- Price
- ALXO $0.56
- SCNX $0.88
- Analyst Decision
- ALXO Strong Buy
- SCNX
- Analyst Count
- ALXO 6
- SCNX 0
- Target Price
- ALXO $3.30
- SCNX N/A
- AVG Volume (30 Days)
- ALXO 456.6K
- SCNX 76.0K
- Earning Date
- ALXO 05-08-2025
- SCNX 05-12-2025
- Dividend Yield
- ALXO N/A
- SCNX N/A
- EPS Growth
- ALXO N/A
- SCNX N/A
- EPS
- ALXO N/A
- SCNX N/A
- Revenue
- ALXO N/A
- SCNX $146,901.00
- Revenue This Year
- ALXO N/A
- SCNX N/A
- Revenue Next Year
- ALXO N/A
- SCNX N/A
- P/E Ratio
- ALXO N/A
- SCNX N/A
- Revenue Growth
- ALXO N/A
- SCNX N/A
- 52 Week Low
- ALXO $0.41
- SCNX $0.69
- 52 Week High
- ALXO $10.97
- SCNX $23.77
- Technical
- Relative Strength Index (RSI)
- ALXO 59.08
- SCNX N/A
- Support Level
- ALXO $0.44
- SCNX N/A
- Resistance Level
- ALXO $0.48
- SCNX N/A
- Average True Range (ATR)
- ALXO 0.05
- SCNX 0.00
- MACD
- ALXO 0.02
- SCNX 0.00
- Stochastic Oscillator
- ALXO 99.16
- SCNX 0.00
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.